AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- Yale University obstetrics and gynecology researchers argued in a recent paper that the design of the Women's Health Initiative study was such that it could not have detected cardioprotective effects of hormone replacement therapy in postmenopausal women.
F. Naftolin and colleagues wrote in Fertility & Sterility, "The Women's Health Initiative (WHI) randomized controlled trial failed to show cardioprotection by estrogen plus progestin treatment of postmenopausal women. But by design, the WHI population was 10-fold underpowered to show cardioprotection of women starting hormone treatment during the menopausal transition.
"Thus, observational studies that showed cardioprotection in such women remain the only applicable clinical guide to this issue," they said.
The authors called for randomized controlled trials, which they said "are urgently needed to test cardioprotection in women ...
Source: HighBeam Research, Design of WHI design could not detect HRT cardioprotective effects.